FDA Backs Off Asbestos Tests in Talc Cosmetics Amid Pushback
Published Date: 11/28/2025
Proposed Rule
Summary
The FDA is hitting pause and withdrawing its plan to require specific tests for asbestos in talc-based cosmetics after hearing lots of feedback. This affects cosmetic makers who would have had to test and keep records to keep their products safe and legal. No new rules or costs are coming right now, but the FDA will rethink and revisit this soon.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Testing/Recordkeeping Requirement Withdrawn
If you make talc-containing cosmetics, the FDA has withdrawn the December 27, 2024 proposed rule that would have required you to test talc or talc-containing products for asbestos and keep records. The withdrawal is effective November 28, 2025, so those specific testing and recordkeeping obligations are not being imposed now.
Consumers Not Covered By Proposed Tests Now
Because the FDA withdrew the December 27, 2024 proposed rule on November 28, 2025, users of talc-containing cosmetic products are not covered today by any standardized testing requirement the proposal would have created. The Agency said it will reconsider how to reduce asbestos exposure in talc-containing cosmetics.
FDA Will Issue New Proposed Rule Later
The FDA said it will issue a new proposed rule to meet its obligations under section 3505 of the Modernization of Cosmetics Regulation Act of 2022. Manufacturers should expect the Agency to revisit standardized asbestos testing in talc-containing cosmetics after further consideration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-21346 — Air Plan Approval; Missouri; Reporting Emission Data, Emission Fees, and Process Information
The EPA is proposing updates to Missouri’s air pollution rules that affect businesses reporting emissions and paying fees from 2025 to 2028 and beyond. They’re adding a new hazardous chemical to the list and making some small rule tweaks, but air quality won’t change. If you’re a Missouri company dealing with emissions, get ready for these updates and consider sending your comments by the end of 2025.
Next: 2025-21409 — Airworthiness Directives; Schempp-Hirth Flugzeugbau GmbH Gliders
If you own a Schempp-Hirth Standard Cirrus glider, the FAA wants you to know about a safety update. They’re changing the rules to fix a potential problem and asking for your feedback by January 12, 2026. This might mean some inspections or fixes soon, so keep an eye on your wallet and calendar!